It began one evening on a paper napkin. No, really.

After the acquisition of endometrial ablation innovator Novacept in 2004, a team of women’s health veterans couldn’t stop envisioning a better, non-hormonal solution for heavy periods. Then, one night in 2008, they found themselves with a paper napkin, a pen, and their growing passion to end AUB.

“We asked ourselves, if we could do it all over again, what would we do differently? What changes would we make? So we sketched out a new and improved device on a napkin, and that night Minerva Surgical was born. Seven years later Minerva ES was approved by the FDA.”

AUB is a serious problem

In the prime of their lives, with significant personal and professional responsibilities, 1 in 3 women shoulder the additional burden of pain, heavy bleeding, fatigue and depression–just some of the symptoms associated with AUB¹.

One-third of outpatient visits to the gynecologist are for AUB, and AUB accounts for more than 70% of all gynecologic consults in the perimenopausal and post-menopausal years². This common condition often results in a hysterectomy due to benign causes if not treated.

Under-treated, under-reported and normalized

“Since launching Minerva ES in 2015, we’ve learned a lot about the impact AUB has on women and their daily lives. Hearing first hand how women suffer with fibroids, polyps and heavy periods moved us to double down.”

“In 2020 we acquired three additional devices for the treatment of AUB, creating a complete, best-in-class intrauterine care kit. Now we can make swift progress toward our goal of providing device-enabled solutions for AUB that are uterus-sparing, minimally invasive, safe and effective.”

“By treating the root causes of AUB, physicians give women the best chance of avoiding a hysterectomy.”

Resectr - Tissue Resection Device

Product Details